ONUREG (azacitidine) for the Treatment of Acute Myeloid Leukaemia (AML)
Azacitidine acts as an oral hypomethylating agent. Credit: Bristol Myers Squibb.
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.ContinueLearn more